Addex Therapeutics Slips To Q2 Net Loss With Lower Income

Addex Therapeutics (ADXN) reported a Q2 net loss of 1.84 million Swiss Francs, a substantial reversal from a 12.88 million Francs profit in the prior year, resulting in a total loss per share of 0.02 Francs. The biopharmaceutical company's net loss from continuing operations also widened to 1.96 million Francs, accompanied by a significant decline in income. Concurrently, CEO Tim Dyer announced an option agreement with Sinntaxis to expand intellectual property for mGlu5 NAMs in brain injury, with plans to further explore dipraglurant's clinical activity in this indication.

Analysis

Addex Therapeutics (ADXN) reported a significant deterioration in its second-quarter financial performance, swinging to a net loss of 1.84 million Swiss Francs from a 12.88 million Francs profit in the prior-year period. This reversal is primarily attributable to the near-complete absence of profit from discontinued operations, which contributed 14.34 million Francs a year ago versus only 0.12 million Francs in the current quarter. More critically for assessing core operational health, the net loss from continuing operations widened to 1.96 million Francs from 1.46 million Francs, as income declined sharply to 0.036 million Francs. This resulted in a total loss per share of 0.02 Francs, a stark contrast to the 0.13 Francs earnings per share recorded previously. In a forward-looking strategic move, the company entered an option agreement with Sinntaxis to bolster its intellectual property for mGlu5 NAMs, signaling a commitment to advancing its clinical pipeline for dipraglurant in the brain injury indication despite the current financial pressures.

Key Decisions for Investors

• Investors should heavily scrutinize the company's cash burn rate and balance sheet, as widening losses from continuing operations and minimal income increase the risk of future dilutive financing.
• Focus on the performance of continuing operations rather than the headline year-over-year net income comparison, as the prior year's profit was skewed by a significant, non-recurring gain from discontinued operations.
• The stock's value is primarily tied to its clinical pipeline, so monitor for specific milestones related to the dipraglurant program and the Sinntaxis agreement, as these will be more significant catalysts than near-term financial results.